BAYONET Trial: Staged Combination With Encorafenib, Binimetinib, Plus Cetuximab Following Encorafenib Plus Cetuximab for BRAF V600E-Mutant Metastatic Colorectal Cancer

    June 2024 in “ ESMO Gastrointestinal Oncology ”
    Y. Matsubara, H. Bando, D. Kotani, Yoshinori Kagawa, K Harada, Hiroki Osumi, Naoki Izawa, Takahiro Kawakami, S. Boku, Tomoharu Matsumoto, M. Wakabayashi, T. Yoshino
    Image of study
    TLDR The combination treatment showed a higher response rate but no significant survival benefits.
    The BAYONET trial is a phase II study involving 30 participants with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who are refractory to standard encorafenib plus cetuximab therapy. It evaluates the efficacy and safety of adding binimetinib to this regimen, focusing on the 12-week progression-free survival rate. Although the triplet therapy showed a higher response rate in previous studies, it did not significantly improve survival, indicating a need for further research into resistance mechanisms, which is being explored through circulating tumor DNA analysis. The findings may guide future treatment strategies for overcoming resistance in mCRC.
    Discuss this study in the Community →